Premium
Mycophenolate mofetil in dysimmune neuropathies: A preliminary study
Author(s) -
Benedetti Luana,
Grandis Marina,
Nobbio Lucilla,
Beronio Alessandro,
Ghiglione Elisabetta,
Manzino Marcello,
Primavera Alberto,
Mancardi Gianluigi,
Sche Angelo
Publication year - 2004
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20024
Subject(s) - excellence , neuroscience , medicine , psychology , philosophy , epistemology
Brief summary \ud\udMycophenolate mofetil (MM) is an immunosuppressant that has been used successfully for preventing the rejection of renal, heart, or liver transplants and for the\udtherapy of immune-mediated diseases. It shows modest side effects and has a lower risk for late malignancies compared with other immunosuppressive drugs.\udRecently, MM has been used also for the treatment of myasthenia gravis, polymyositis, chronic inammatory demyelinating polyradiculoneuropathy (CIDP), andmultifocal motor neuropathy (MMN).\udWe treated four patients with possible, probable, or denite MMN and two with CIDP\udwho were on large doses of intravenous immunoglobulins (IVIg), with the hope of reducing or with drawing IVIg while maintaining a satisfactory and stable clinical state. Four patients were also receiving other immunomodulating agents. Patients receivedoral MM in a dosage of 1 g twice daily, for an average of 9 months (range, 6–12 months). Prior to MM treatment, all patients underwent several attempts to reduce IVIg dosage, resulting in clinical worsening, even in subjects receiving other immunomodulating agents. Patients were evaluated at baseline and each month thereafter, using the Medical Research Council (MRC) sumscore and the Immune Neuropathy Course and Treatment (INCAT) arm and leg disability scores.\udThe values of the INCAT scale at baseline ranged from 0 to 3 (mean, 1.5). Full blood count,\udrenal and liver function, and serum amylase levels were monitored every 2 months.\udWe found that MM, in patients with MMN and CIDP, is effective in reducing IVIg requirement and in replacing other, more toxic, drugs. Only one patient with MMN relapsed, after 4 months, perhaps because of longer duration of disease, as previously observed in another series of patients. \udWe suggest that the association of MM with IVIg in dysimmune neuropathies, and particularly in MMN, is effective in reducing the dosage of immunoglobulins. Randomized controlled trials are warranted to further clarify the role of this immunosuppressant in the therapy of MMN and CIDP